

The Impact of Apo E Genetic Polymorphism on Carotid intimal-medial Thickness in Diabetic Elderly

KEYWORDS	Apolipoprotein E; Carotid intima-media thickness; Carotid plaques					
Dr. Mota	ssem Salah Amer	Dr. Laila Ahmad Abdurrahman				
Professor of Geriatric Faculty of medicine, Ai	Medicine and Internal Medicine, n Shams University, Cairo, Egypt.	Professor of Radiology, Faculty of medicine, Ain Shams University, Cairo, Egypt.				
Dr. Rand	a Reda Mabrouk	Dr. Manar Mostafa Adel				
Professor of clinical pa Shams Uni	thology, Faculty of medicine, Ain versity, Cairo, Egypt.	Assistant professor of Geriatric medicine, Faculty of medicine, Ain Shams University, Cairo, Egypt.				
Dr. Doaa M	ohamed Abdel Aziz	Dr. Sherine Mohamed Ibrahim Sharara				
Lecturer of clinical pat Shams Uni	hology, Faculty of medicine, Ain versity, Cairo, Egypt.	Lecturer of Radiology, Faculty of medicine, Ain Shams University, Cairo, Egypt.				

Rasha Ahmed Mohammed Ali

Assistant lecturer of Geriatric Medicine and Gerontology, Faculty of medicine, Ain Shams University, Cairo, Egypt. (Corresponding author)

ABSTRACT Aim: to investigate associations between ApoE polymorphisms and CIMT in elderly diabetics

Methods: This was a case- control study, ApoE genotyping was tested, total cholesterol, HDL-C, LDL-C, TG and bilateral carotid ultrasound was done in ninety elderly subjects who were divided into thirty elderly diabetic subjects with cardiovascular complications (group A), thirty elderly diabetic subjects without cardiovascular complications (group B) and thirty elderly subjects without DM (group C).

Results: The carotid plaques were significantly more frequent among those have E4 alleles in diabetic patients with cardiovascular complications while no significant association between different ApoE alleles and mean CIMT.

Conclusions: ApoE gene polymorphisms are significantly associated with increased risk of carotid plaque formation not intimal media thickness (IMT).

INTRODUCTION

It is still unsettled whether ApoE4 genotype is associated [1] or not associated with carotid atherosclerotic plaques [2] and the relationship between ApoE and vascular disease has been the subject of a considerable amount of research. However, this relationship is far from clearly defined.

This deficiency appears to be due to a multitude of factors. Among these are differences in ethnicity, age (and possibly gender), diagnostic criteria, and environmental factors (eg, diet and smoking) that have contributed to the contradictory findings [3].

ApoE is a plasma glycoprotein of 34 kDa with 299-amino acids [4] human ApoE gene is located on the long arm of chromosome 19 (19q13.2) and consists of four exons and three introns spanning 3,597 nucleotides [5]. Genetic variations in the ApoE gene exon 4 lead to three common gene variants (alleles), E2, E3, and E4, which code for three major isoforms (E2, E3, and E4), resulting in six common genotypes : three homozygous genotypes E2/E2, E3/ E3, E4/E4 and three heterozygous genotypes: E2/E3, E2/ E4, E3/E4.

Carotid atherosclerosis was considered a surrogate marker for coronary atherosclerosis and thus, the measurement of

IMT by ultrasound provides a quantitative basis for the extent of atherosclerosis [6], Although Apo E polymorphism is considered as a genetic risk factor for coronary heart disease [7,8] studies examining its association with different CIMT values have not been conclusive [9,10].

As a part of our ongoing study to evaluate the effect of ApoE polymorphisms on CIMT and abdominal aortic diameter in diabetic elderly Egyptian patients, the data represented in the current research article concerned with the effect of APOE polymorphisms on CIMT, while the other part which investigate the relation between APOE polymorphisms and abdominal aortic diameter will be discussed in another research article.

SUBJECTS and METHODS Study population and design

This study was a case - control study involved 90 elderly participants were divided into 3 groups: **Group A:** Thirty elderly patients sixty years old and above, diagnosed to have type 2 diabetes mellitus with cardiovascular complications. **Group B:** Thirty elderly patients sixty years old and above diagnosed to have type 2 diabetes mellitus without cardiovascular complications. **Group C (control group):** Thirty elderly subjects sixty years old and above, without DM. All enrolled participants provided written informed consent prior to inclusion into the study

Laboratory Measurements

Venous blood (6 ml) was withdrawn aseptically into a sterile disposable syringe from each patient and control where, 5 ml were placed in EDTA tube for APOE genotyping and 2 ml were collected plain vacutainers to be clotted and centrifuged for measurement of total cholesterol, HDL-C, LDL-C ,TG and fasting glucose. On Synchron CX-9 autoanalyzer (Beckman Instruments Inc.; Scientific Instruments Division, Fullerton, CA 92634, 3100, USA). The laboratory work was conducted at Clinical Pathology Department, Ain shams university .

Genotyping of Apo E was performed using polymerase chain reaction and restriction fragment length polymorphism. Genotyping of three common alleles (E2, E3, and E4) of the Apo E gene was performed. Genomic DNA was extracted from human blood cells using QIAamp DNA Mini Kit (Qiagen, USA) the extracted DNA was stored at -20°C until processed. The primers used were 5'-ACA-GAATTCGCCCCGGCCTGGTACAC-3' and 5'-TAAGCTTG-GCACGGCTGTCCAAGGA-3' as described by Emi et al. (1988) (11) and prepared by Promega (Madison,USA). PCR product were carried out in volume of 50 µl containing 5 µl genomic DNA, 25 µl of the ready to use master mix supplied by Qiagen, 2.5µl (25 pmol) of forward primer, 2.5 µl (25 pmol) of reverse primer and 15 µl of deionized water. The PCR conditions were an initial denaturation at 95°C for 3 minutes and 40 cycles consisting of denaturation at 95°C for 15 seconds, annealing at 62°C for 15 seconds, extension at 72°C for 45 seconds before a final extension at 72°C for 4 minutes. Restriction digestion of the amplified product was performed using 0.5 µl (10 units/ µl) Hha1 restriction enzyme supplied by promega. Site of restriction: (5'GCG⁻C 3') (3' C⁻GCG 5'). The enzyme was added to 5 µl of PCR amplified product, 12.3 µl deionized water, 2 µl of buffer (10 x of 60mM tris-Hcl) and 0.2of µl acetylated bovine serum albumin (BSA)(10ug/ µl), followed by gentle mix. Then the tubes were placed on a heat block for 3 hours at 37°C. The enzyme was inactivated at 65°C for 15 minutes. As experimental control: no-enzyme "mock" digest was used

Amplified product of DNA samples and restriction fragments were run on 8% polyacrylamide gel and stained with ethidium bromide. DNA molecular weight marker was also run to identify the site of bands (20 bp DNA ladder supplied by (Promega, USA). Digestion of the amplified product (270 bp) by the restriction enzyme Hha1 resulted in the following different individual genotypes that were categorized based on the following band length criteria:E2/2=91 ,83,38;E3/3:91,48,38,35;E4/4:72,48,38,35;E2/3:91,83,48,38 ,35;E2/4:91,83,72,48,38,35;E3/4:91,72,48,38,35. (figure 1)

Carotid Ultrasound

Both left and right CCAs were depicted. With the aid of an Alpinion-Korae- E-CUBE-9 ultrasound unit equipped with a 7.5-MHz transducer. The sonographers measured CIMT of the posterior wall of the right and left common carotid arteries, 1.5 cm proximal to the bifurcation. The mean value of the right and left common carotid IMT was used for analysis.

RESULTS

The study population characteristics are described in Table 1. There is no significant difference between study groups regarding age and sex, the mean HDL level is significantly higher in control group than other groups. As regard the frequency of ApoE allele among study groups, ApoE2 allele is significantly more frequent in-group B, C compared to group A while ApoE3 allele is significantly more frequent in group A and group C compared to group B. In addition, ApoE4 allele is more frequent in group A, B comparing to group C with no statistical significance. Both CIMT and presence of carotid plaques are significantly higher in group A in comparison to control group. After pooling the overall subjects, the results showed higher mean LDL among ApoE4 carrier subjects compared to E3 and E2 and the difference is significant statistically (P=0.02). The results revealed that there was no significant association was observed between ApoE alleles and mean CIMT in the whole study population while the presence of carotid plaques are significantly more frequent among those have E4 allele compared to those have E3 allele in group A.

DISCUSSION

Most studies of the ApoE polymorphism have shown carotid IMT to be lower in carriers of the E2 allele and higher in carriers of the E4 allele, compared with E3/E3 homozygotes [12-14].These associations have not been totally consistent however, with de Andrade et al. and Hanon et al. showing higher CIMT in E2 carriers [15,16] Zannad et al showing higher CIMT in E3/E3 homozygotes compared with E2 or E4 carriers but on the right side only [17] and several studies [18-26], showing no association. The results are also varied depending on the country, gender, and age subgroups. CIMT values increased in the North American and Australian Apo E4/ E4 men in ARIC and CUDAS studies [14, 27]. However, no such differences were found among the genotype subgroups in Rotterdam study conducted on Central European elderly participants [28].

The current study results were consistent with those found in a Calmarza et al., (2015) study who assessed the CIMT

and ApoE genotypes in 171 individuals older than 40 years. Their results showed no significant difference among E3, E4 and E2 groups regarding CIMT, however ApoE4 allele was associated with higher levels of LDL-C but not with early atherosclerosis as assessed by CIMT [26]. Similarly, the studies carried out by Beilby et al., (2003) who perform a cross-sectional study of 1111 randomly selected community subjects. The multivariate modeling had suggested that, in men there was a log-additive trend in the risk of carotid plaque with increasing numbers of E4 alleles while, In women the E2 allele was associated with a lower risk for plaque development relative to the E3 allele. Also their results showed that ApoE genotypes were not associated with CIMT in the whole study population [14].

The controversy of results of relation between ApoE polymorphism and CIMT, can be explained as there are other environmental and genetic factors are involved in the pathogenesis of carotid atherosclerosis in diabetic patients.

As the genetic and environmental factors interact to influence a person's biological makeup, including the predisposition to different diseases. There are several biological mechanisms that affect expression of genes ("switched" on or off) can be affected positively and negatively by environmental factors, such as exercise, diet, chemicals, or smoking, alcohol, to

which an individual may be exposed.

CONCLUSIONS

There was an association between ApoE4 and dyslipidemia in the form of higher mean LDL among ApoE4 carrier subjects. The mean carotid intimal thickness is considered as an early marker of atherosclerotic disease, it was the highest in diabetic patients with cardiovascular complications compared to diabetic patient without cardiovascular complications and also healthy control .Carotid plaques were significantly higher in diabetic patients with cardiovascular complications compared to controls. Moreover, Carotid plaques were significantly more frequent among those have E4 alleles while there was no significant association was between ApoE genotypes and mean CIMT.

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

Table	(1):	Comparison	between	study	groups	regarding	age	(years)	and	sex,	hypertension,	laboratory	findings	and
CIMT														

Variable	Group A (N=30)	Group B (N=30)	Control (N=30)	P _{A/B}	P _{A/C}	P _{B/C}
Age Mean±SD Range	65.4±6.6 60.0–85.0	65.3±6.6 60.0–86.0	67.2±6.4 60.0–82.0	0.969^	0.285^	0.268^
Sex (n, %) Female Male	21 (70.0%) 9 (30.0%)	21 (70.0%) 9 (30.0%)	17 (56.7%) 13 (43.3%)	1.000#	0.284#	0.284#
Cholesterol Mean±SD Range	161.7±56.9 62.0–300	191.0±62.3 93.0–350	190.9±55.1 95.0–299	0.062	0.048*	0.991
TG (mg/dL) Mean±SD Range	135.8±70.8 35.0–335	151.6±76.6 68.0–400	146.4±76.2 38.0–391	0.411	0.580	0.793
LDL (mg/dL) Mean±SD Range	92.0±36.6 21.0–196	112.0±47.8 35.0–219	108.2±43.9 47.0–230	0.075	0.128	0.750
HDL (mg/dL) Mean±SD Range	33.6±13.1 8.0–71.0	38.0±11.1 11.0–65.0	46.8±14.3 16.0–73.0	0.165	^0.001*	0.009*
E2 allele	0 (0.0%)	16 (53.3%)	14 (46.7%)	^0.001*	^0.001*	0.606
E3 allele	18 (60.0%)	3 (10.0%)	7 (23.3%)	^0.001*	0.166	0.004*
E4 allele	12 (40.0%)	11 (36.7%)	9 (30.0%)	0.791	0.417	0.584
CIMT (mm) Mean±SD Range	1.2±0.4	1.1±0.2 0.8–1.7	1.0±0.2 0.6–1.6	0.060	0.040*	0.755
Carotid plaques	14(46.7%)	11(36.7%)	5 (16.7%)	0.432	0.012*	0.080

^Independent t-test, #Chi square test, #Chi square test, &Fisher's Exact test

Table (2):	Comparison	between	different	APOE	genotypes	regarding	Total	cholesterol,	Triglyceride,	HDL	and	LDL
among stu	udied groups											

	E2 allele N=30	E3 allele N=28	E4 allele N=32	F	Р	
Total cholesterol	172.6±60.2	178.2±67.0	191.7±50.0	0.8	0.4	
Triglyceride	158.4±78.0	145.9±85.3	130.3±57.4	1.1	0.3	
HDL	40.3±14.1	35.4±13.8	42.1±13.3	1.8	0.1	
LDL cholesterol	97.4±45.1	93.8±34.3	120.8± 44.7	3.7	0.02*	E4 vs E2,E3

Comparison of CIMT and presence of carotid plaques as regard APOE alleles within group A

RESEARCH PAPER Volume : 5 Issue : 11 November 2015 ISSN - 2249-555							
Variable	E3 (N=18)	E4 (N=12)	Р				
CIMT (mm)	1.1±0.3	1.3±0.4	^0.079				
Carotid plaques	5 (27.8%)	9 (75.0%)	#0.011*				

^Independent t-test, #Chi square test,



Figure (1): APO E genotypes by polyacrylamide gel electrophoresis: lane 1 shows ladder 20 bp, lane 5,9,10 shows E2/E2 genotype, lane 6,7,11 shows E3/E4 genotype, lane 2, 4,3,12 shows E4/E4 genotype and finally lane 8, 13 shows E3/E2 genotype.

REFERENCE

[1] Debette S, Lambert JC, Gariepy J, et al: New insight into the association of apolipoprotein E genetic variants with carotid plaques and intima-media thickness. Stroke 2006;37:2917–2923. [2] Gronroos P, Raitakari OT, Kahonen M, et al : Relation of apolipoprotein E polymorphism intima-media thickness. Stroke 2006;37:2917–2923. [2] Gronros P, Raitakari OT, Kahonen M, et al : Relation of apolipoprotein E polymorphism to markers of early atherosclerotic changes in young adults--the Cardiovascular Risk in Young Finns Study. Circ J 2008;72(1):29–34. [3] Kolovou G, Daskalova D and Mikhailidis DP: Apolipoprotein E Polymorphism and Atherosclerosis. Angiology J 2003;54:59-71. [4] Singh PP, Singh M and Mastana SS: APOE distribution in world populations with new data from India and the UK. Ann Hum Biol 2006;33:279-308. [5] Eichner JE, Dunn ST, Perveen G, et al: Apolipoprotein E Polymorphism and Cardiovascular Disease: A HuGE Review. Am J Epidemiol 2002;155:487-495. [6] Graner M, Kahri J, Varpula M, et al: Apolipoprotein E Polymorphism is associated with both carotid and coronary atherosclerosis in patients with coronary artery disease. Nutr Metab Cardiovasc Dis 2008;18:271-277. [7] Eichner JE, Kuller LH, Orchard TJ, et al : Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. Am J Cardiol 1993;71:160-165. [8] Wilson PW, Schaefer EJ, Larson MG, et al: Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc Biol 1996;16:1250-1255. [9] Fox, CS, Polak JE Chazzo, L et al: Genetic and environmental cortifications at therosclerosis in pentitybility of carotid intirhazmedia thickness in men and women heritability of carotid intirhazmedia thickness Polak JF, Chazaro I, et al: Genetic and environmental contributions to atherosclerosis phenotypes in men and women heritability of carotid intima-media thickness in the Framingham Heart Study. Stroke 2003;34:397–401. [10] Zannad F, Visvikis S, Gueguen R, et al : Environmental and genetic determinants of intima-media thickness of the carotid artery. Clin Exp Pharmacol Physiol 2001;28(12):1007–1010. [11] Emi M, Wu L L, Robertson M A, et al (1988): Genotyping and sequence analysis of of the carotid artery. Clin Exp Pharmacol Physiol 2001;28(12):1007–1010. [11] Emi M, Wu L L, Robertson M A, et al (1988): Genotyping and sequence analysis of apolipoprotein E isoforms. Genomics; 3: 373-379. [12] Cattin L, Fisicaro M, Tonizzo M, Valenti M, Danek GM, Fonda M, Da Col PG, Casagrande S, Pincetri E, Bovenzi M, Baralle F: Polymorphism of the apolipoprotein E gene and early carotid atherosclerosis defined by ultrasonography in asymptomatic adults. Arterioscler Thromb Vasc Biol 1997, 17:91–94. [13] Terry JG, Howard G, Mercuri M, et al : Apolipoprotein E polymorphism is associated with segment-specific extracranial carotid artery intima-media thickening. Stroke 1996;27:1755–1759. [14] Beilby JP, Hunt CJ, Palmer LJ, et al: Apolipoprotein E Gene Polymorphisms Are Associated With Carotid Plaque Formation but Not With Intima-Media Wall Thickening: Results From the Perth Carotid Ultrasound Disease Assessment Study (CUDAS). Stroke 2003;34:869-874 [15] De Andrade M, Thandi I, Brown S, et al: Relationship of the apolipoprotein E polymorphism with carotid artery atherosclerosis. Am J Hum Genet 1995;56:1379–1390. [16] Hanon O Girerd X, Luong Y, Jeunema'tre X, et al: Association between the apolipoprotein E polymorphism and arterial wall thickness in asymptomatic adults. J Hypertens 2000;18:431–436. [17] Zannad F, Visvikis S, Gueguen R, et al: Genetics strongly determines the wall thickness of the left and right carotid arteries. Hum Genet 1998;103:183–188. [18] Kogawa K, Nishizawa Y, Hosoi M, et al: Effect of polymorphism fapolipoprotein E and angiotensin-converting enzyme genes on arterial wall thickness. Diabetes 1997;46:682–687. [19] Schmidt R, Schmidt H, Fazekas F, et al: Apolipoprotein E polymorphism and silent microangiopathy-related cerebral damage. Results of the Austrian Stroke Prevention Study. Stroke 1997;28:951–956. [20] Sass C, Zannad F, Herbeth B, et al: Apolipoprotein E4, lipoprotein E4, and angiotensin and femoral arteries in healthy subjects from the Stanislas cohort. Atherosclerosis1998;140:89-95. [21] Guz G, Nurhan OF, Sezer S, et al: Effect of apolipoprotein E and temoral arteries in healthy subjects from the Stanislas cohort. Atherosclerosis 1998;140:89–95. [21] Guz G, Nurhan OF, Sezer S, et al: Effect of apolipoprotein E polymorphism on serum lipid, lipoproteins, and atherosclerosis in hemodialysis patients. Am J Kidney Dis 2000;36:826–836. [22] Tabara Y, Kohara K, Nakura J, et al: Risk factor-gene interaction in carotid atherosclerosis: effect of gene polymorphisms of renin-angiotensin system. J Hum Genet 2001;46:278–284. [23] Zuliani G, Cherubini A, Volpato S, et al: Genetic factors associated with the absence of atherosclerosis in octogenarians. J Gerontol A Biol Sci Med Sci 2002;57:611–615. [24] Djousse L, Myers RH, Province MA, et al: Influence of apolipoprotein E, smoking, and alcohol intake on carotid atherosclerosis: National Heart, Lung, and Blood Institute Family Heart Study. Stroke 2002;33:1357-1361. [25] Asakimori Y, Yorioka N, Tanaka J, Kohno N: Effect of polymorphism of the endothelial nitric oxide synthase and apolipoprotein E genes on carotid atherosclerosis in hemodialysis patients. Am J Kidney Dis 2003;1941:822–832. [26] Calmarza P, Trejo J M , Lapresta C, et al : Different Apolipoprotein E Polymorphisms Are Not Associated with Different Carotid Intima-Media Thickness Values in a Sample of Spanish General Populaton. Int Cardiovasc Res J 2015;9(2):83-88. [27] Volcik KA, Barkely RA, Hutchinson RG, et al : Apolipoprotein E polymorphisms predict low density lipoprotein cholesterol levels and carotid artery wall thickness but not incident coronary heart disease in 12,491 ARIC study participants. Am J Epidemiol 2006;164:342–348. [28] Slooter AJ, Bots ML. Havekes LM et al: Apolipoproteine factoria darterosclerosis the Rotterdam study. Stroke 2001;32:1927–1922 ML, Havekes LM, et al: Apolipoprotein E and carotid atherosclerosis: the Rotterdam study. Stroke 2001;32:1947-1952.